DLBCL: novel risk stratification method links TIL-Ts to survival

  • Chen Z & al.
  • Ann Hematol
  • 30 Oct 2018

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A low proportion of tumor-infiltrating T lymphocytes (TIL-Ts) and a high ratio of CD4:CD8 ratio of TIL-Ts within the tumor microenvironment may identify a subset patient with de novo diffuse large B-cell lymphoma (DLBCL) at higher risk of inferior survival.

Why this matters

  • Few DLBCL studies have focused on the prognostic role of TIL-Ts within the tumor microenvironment.

Study design

  • Study to investigate an association between TIL-Ts as a proportion of the tumor microenvironment and outcomes in 66 patients with de novo DLBCL.
  • 61 (range, 8-83) years median patient age.
  • Funding: National Natural Science Foundation of China, Sichuan Science and Technology Program.

Key results

  • In multivariate analysis, the following were independent risk factors for inferior survival:
    • Low TIL-T proportion (
    • High CD4:CD8 ratio (≥1.2 vs
  • In risk analysis, patients were stratified into 3 groups; patients in the high-risk group (low TIL-Ts, high CD4:CD8 ratio) demonstrated inferior survival vs:
    • Intermediate-risk patients (low TIL-Ts, low CD4:CD8 or high TIL-Ts, high CD4:CD8): P=.025.
    • Low-risk patients (high TIL-Ts, low CD4:CD8 ratio): P=.002.

Limitations

  • Retrospective data.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit